Gland Pharma profit rises 12 percent to Rs 184 crore in Q2
Gland Pharma Ltd has posted a 12 per cent year-on-year rise in profit after tax (PAT) at Rs 84 crore for the quarter ended September 2025, supported by robust contributions from its CDMO subsidiary, Cenexi.
In the same period last fiscal, the Hyderabad-based pharmaceutical firm had reported a PAT of Rs 163 crore.
Revenue from operations grew to Rs 1,487 crore in the July–September quarter, compared to Rs 1,406 crore in the corresponding quarter of the previous fiscal, the company said.
"Gland Pharma delivered a strong first half of FY26, with Revenue growth of 7% and PAT up by 30% YoY. We expect stronger momentum in the second half, driven by new launches and Cenexi's recovery. Our investments in global CDMO expansion, capacity enhancement in high-end modalities and complex injectables pipeline continue to strengthen our foundation and support sustainable growth and long-term value for all stakeholders," Gland Pharma Executive Chairman Srinivas Sadu said.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.